Private Equity 8 Hours

Last updated: May 22, 2026, 11:30 AM ET

Secondary Market Activity Frontenac prepares to sell its CV asset MCE as Churchill Asset Management and 50 South Capital co‑lead the transaction, extending Frontenac’s exposure to industrials while providing liquidity for its broader portfolio. The move follows a wave of secondary sales that have allowed sponsors to rebalance holdings without triggering a full exit, a trend that has gained momentum as credit markets tighten.

Healthcare Consolidation Charterhouse, Iron Path and Revelar target pain‑management platforms alongside a recent orthopedic‑focused merger backed by Charlesbank illustrate private equity’s aggressive push into specialty care. The five deals, valued collectively at roughly $1.2bn, aim to create integrated service networks that capture rising demand for chronic‑pain therapies and joint‑replacement procedures. By bundling add‑on acquisitions with platform companies, firms hope to achieve cost synergies and improve bargaining power with insurers.

Consumer‑Health Expansion Avista and Damier move to acquire Belgian vitamins maker Sanotact in a transaction reported at €150 m, expanding Damier Group’s health‑product footprint and giving Avista a foothold in the European nutraceutical market. The deal aligns with a broader wave of PE interest in consumer‑health brands that benefit from post‑pandemic wellness spending, and it positions the buyers to leverage Sanotact’s established distribution channels across the EU.

Growth‑Stage Funding Outlook Scaleup Europe Fund outlines a €5bn mandate that could back more than 100 high‑growth companies, signaling sustained investor appetite for late‑stage tech and clean‑energy ventures despite a modest slowdown in early‑stage fundraising. The fund’s size reflects confidence that Europe’s scaling ecosystem can deliver returns comparable to U.S. counterparts, especially as cross‑border capital flows resume.

Strategic Yield‑Focused Strategies Todd Miller outlines Partners Group’s total‑return approach targeting mature heavy‑industry assets, a niche that has attracted yield‑seeking capital amid volatile equity markets. Concurrently, CVC and GBL announced a take‑private deal for Recordati, valued at €3.5bn, underscoring private equity’s willingness to deploy large‑scale financing for established pharmaceutical firms with stable cash flows.

Technology IPO Pipeline Oura files for a New York IPO as the smart‑ring maker seeks to raise up to $300 m, leveraging its health‑monitoring data platform to tap public‑market valuations. The filing adds to a growing list of consumer‑tech companies turning to U.S. exchanges, a trend driven by the desire for greater liquidity and brand visibility.